Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 16;12:2628. doi: 10.1038/s41598-022-06629-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Comparison of antibody levels and neutralization activities against both the wildtype RBD and N501Y RBD proteins with convalescent sera. (A) Linearity of the anti-WT-RDB and anti-N501Y-RBD detected in the convalescent sera with a slope of 1.087 (r² = 0.927). (B) Neutralization data from COVID-19 convalescent sera and negative controls. The convalescent sera had specific neutralizing activity against N501Y-RBD (P < 0.0001). (C) Linear regression analysis of the ACE2 bound the WT and N501Y RBD detected using the COVID-19 convalescent sera with a slope of 3.99 (r² = 0.896, N = 41). (D) N501Y RBD have much higher absolute ACE2 binding than the WT RBD in the presence of neutralizing convalescent sera (P < 0.0001, N = 41).